




RealRate

PHARMACEUTICAL 2022

Iterum Therapeutics plc
Rank 374 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Iterm Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Iterm Therapeutics plc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Iterm Therapeutics plc is the variable Other Net Income, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 167%, being 108% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	83,266
Cost of Goods Sold	0
Intangible Assets	3,435
Liabilities, Current	12,941
Liabilities, Non-Current	10,366
Other Assets	4,717
Other Compr. Net Income	0
Other Expenses	705
Other Liabilities	17,968
Other Net Income	-66,322
Other Revenues	0
Property and Equipment	91
Research and Development	10,712
Selling, General and Administrative Expense	13,825

Output Variable	Value in 1000 USD
Assets	91,509
Liabilities	41,275
Expenses	25,242
Revenues	0
Stockholders Equity	50,234
Net Income	-91,564
Comprehensive Net Income	-91,564
BaseVar	112,174
ECR before LimitedLiability	27%
Economic Capital Ratio	167%